Answers are grounded in this paper and cite their sources.
Non‑small cell lung cancer (NSCLC) remains refractory to most current therapeutic modalities, largely owing to poor target specificity and inadequate antitumor immune activation. To address these challenges, integrative analysis of single-cell RNA sequencing data and human lung cancer tissue microarrays identified elevated expression of adhesion G protein-coupled receptor F5 (ADGRF5) in NSCLC cells, highlighting its potential as a ligand-addressable target for tumor-selective nanomedicine delivery. Based on this finding, we leveraged fibronectin type III domain‑containing protein 4 (FNDC4), a previously identified high-affinity ligand of ADGRF5. We then constructed FNDC4-displaying biomimetic nanoparticles (termed PLACE@MF) by encapsulating the photosensitizer chlorin e6 (Ce6) and atractylenolide I (ATT‑I) into Poly(lactic‑co‑glycolic acid) (PLGA) cores, and further camouflaging the particles with cell membranes engineered to overexpress FNDC4. Leveraging the ligand-receptor interaction between FNDC4 and ADGRF5, the nanoparticles exhibited markedly enhanced specificity toward NSCLC cells both in vitro and in vivo. Upon light irradiation, Ce6‑mediated photodynamic therapy was able to kill the lung cancer cells directly and trigger immunogenic cell death. Concurrently, ATT‑I upregulated major histocompatibility complex class I (MHC‑I) expression on NSCLC cells, thereby potentiating CD8⁺ T‑cell‑mediated cytotoxicity. In NSCLC tumor‑bearing mouse models, PLACE@MF demonstrated superior therapeutic efficacy, reducing tumor volume to approximately one‑fifteenth of that in the control group. Collectively, this work establishes a ligand-receptor‑based targeting strategy via FNDC4-ADGRF5 axis and offers a promising framework for precision therapy of NSCLC.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: